Following a sluggish summer of deals, we’ve seen a string of buyouts. But will this trend continue?
So far, the first two weeks of October have seen a flurry of activity with four deals worth about $6.7 billion in total. While BMS’s $4.8 billion buy of Mirati was the by far the biggest, this month we also saw AbbVie acquire neurodegenerative disease-focused Mitokinin for $110 million, Eli Lilly’s $1.4 billion purchase of radiopharmaceutical company Point Biopharma and Kyowa Kirin’s $387 million acquisition of gene therapy developer Orchard Therapeutics.
While there’s been a recent uptick in deals, bankruptcy among biotechs is also on the rise. In fact, 2023 has seen a record high number of biotech bankruptcies, BioSpace reported this week—along with a spike in the number of cases in the past couple of years. Among the drivers: the post-COVID economy, a shift toward data-driven financing activity and inflation rates.
On the opposite end of the spectrum, one company that continues its upward financial trajectory is Novo Nordisk, fueled by diabetes drug Ozempic and weight-loss medication Wegovy. On Friday, the Danish drugmaker for the third time this year raised its full-year sales guidance. Earlier this week, Novo halted a Phase III kidney outcomes study of semaglutide—the active ingredient in Ozempic and Wegovy—ahead of schedule due to strong efficacy signals.
It was not welcome news for DaVita, one of the largest providers of kidney care services in the U.S. On Thursday, the dialysis giant raised concerns over Novo’s interim analysis of the kidney outcomes study of semaglutide, pointing to the potentially limited applicability of the findings.
Davita contends that only patients with both type 2 diabetes and chronic kidney disease (CKD) who had previously received standard therapies, such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, were eligible for enrollment in Novo’s study. “Fewer than 10% of all current CKD patients” could satisfy this combination of factors, according to Davita. Regardless, the company said it is still “nearly impossible” to draw definitive conclusions from the Novo study.
Alnylam this week was penalized for not providing enough evidence of its therapy’s benefit. Despite winning the backing of an FDA advisory committee, the agency in a Complete Response Letter declined Alnylam’s bid to expand Onpattro’s label to cardiomyopathy in ATTR amyloidosis. As a result, Alnylam will no longer pursue an expanded indication for the siRNA therapeutic in the U.S.
![GMP mRNA](https://static.packgene.com/wp-content/uploads/2023/07/13.jpg)
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)